Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 36,297 |
|
|||||
| News | - | ||||||
| Day High | 46.04 | Low High |
|||||
| Day Low | 45.40 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vericel Corporation | VCEL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.375 | 0.83% | 45.825 | 12:33:35 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 45.66 | 45.40 | 46.04 | 45.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,803 | 36,297 | $ 45.69 | $ 1,658,276 | - | 29.70 - 53.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:34:52 | 1 | $ 45.7654 | USD |
Vericel Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.21B | 48.29M | - | 197.52M | -3.18M | -0.07 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vericel News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCEL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 43.67 | 47.14 | 42.375 | 45.19 | 328,589 | 2.16 | 4.93% |
| 1 Month | 52.60 | 53.05 | 42.375 | 48.39 | 346,739 | -6.78 | -12.88% |
| 3 Months | 43.01 | 53.05 | 41.58 | 47.13 | 435,976 | 2.82 | 6.54% |
| 6 Months | 34.55 | 53.05 | 32.28 | 41.24 | 468,088 | 11.28 | 32.63% |
| 1 Year | 29.70 | 53.05 | 29.70 | 38.29 | 405,743 | 16.13 | 54.29% |
| 3 Years | 60.25 | 68.94 | 17.30 | 36.70 | 426,459 | -14.43 | -23.94% |
| 5 Years | 17.60 | 68.94 | 6.78 | 30.47 | 504,902 | 28.23 | 160.37% |
Vericel Description
| Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
